MPE launches a report focused on the impact of AL amyloidosis in quality of lifeAL amyloidosis, MPE21 November 2023
ESMO 2023 | Patient Advocacy Track highlights challenges in access, caregiver support and digitalisationConferences, MPE27 October 2023
MPE launches European Amyloidosis Diagnosis Pathway to promote early detection of the rare diseaseAccess, AL amyloidosis26 October 2023
MPE to present at European Society for Medical Oncology (ESMO) Annual Congress 2023Conferences, MPE17 October 2023
EMA CHMP gives positive recommendation to elranatamab for the treatment of relapsed or refractory myelomaAccess, MPE, Myeloma13 October 2023
EMA CHMP recommends non-renewal of marketing authorisation for Blenrep®Access, Myeloma22 September 2023
EMA recommends expansion of melphalan flufenamide (Pepaxti®) marketing authorisationAccess, Myeloma18 September 2023
